[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
November 1996

Radiation Therapy and Ferromagnetic Hyperthermia in the Treatment of Murine Transgenic Retinoblastoma

Author Affiliations

From the Departments of Ophthalmology (Drs Murray and Markoe and Ms Cicciarelli) and Radiation Oncology (Drs Murray and Markoe), Bascom Palmer Eye Institute, University of Miami, Miami, Fla; the Department of Ophthalmology, University of California, San Francisco (Drs O'Brien and Smith); the Departments of Ophthalmology (Dr Steeves) and Radiation Oncology (Drs Albert and Tompkins), University of Wisconsin, Madison; and the Cancer Therapy and Research Center, San Antonio, Tex (Dr Windle).

Arch Ophthalmol. 1996;114(11):1376-1381. doi:10.1001/archopht.1996.01100140576008

Background:  Combined modality therapy for childhood retinoblastoma holds the potential of decreasing treatment-related morbidity while maintaining excellent tumor control rates.

Objective:  To evaluate the efficacy of external beam radiation therapy (EBRT), ferromagnetic hyperthermia (FMH), and the combination of both modalities in the control of ocular tumors in a transgenic murine model of retinoblastoma.

Methods:  One hundred sixty-six mouse eyes from 4-week-old animals transgenically positive for simian virus 40 large T antigen were treated with a total dose of 10, 15, 20, 30, 40, 45, or 50 Gy of EBRT in 5-Gy fractions twice daily, with 48°C or 54°C FMH for 20 minutes, or with combined EBRT at 10 or 30 Gy and 48°C or 54°C FMH for 20 minutes. Serial histologic sections, obtained 8 weeks after treatment, were examined for the presence of tumor.

Results:  The tumor control dose for 50% of eyes (TCD50) treated with EBRT occurred at 27.6 Gy. Ferromagnetic hyperthermia at 48°C cured 30% (6/20) of eyes, while 54°C FMH resulted in a 100% (20/20) cure rate. Combined treatment with 48°C FMH and EBRT exhibited a TCD50 at 3.3 Gy. The thermal enhancement ratio was 8.4. Ferromagnetic hyperthermia at 54°C exhibited tumor cure in all animals, but 25% of eyes were lost owing to secondary treatment complications.

Conclusions:  This represents the first documentation of tumor control via EBRT, ocular FMH, and a combination of these treatment modalities in this murine transgenic retinoblastoma model. The extent of treatment synergy in this model suggests that combined treatment application may allow a reduction in total ocular and periocular radiation dose while maintaining excellent local tumor control.